03 Aug 2015

VIMOVO modified-release (Naproxen / Esomeprazole) - United Kingdom

ATC: M01AE
MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
PROPIONIC ACID DERIVATIVES
VIMOVO modified-release tablets

Last Updated on 03 Aug 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

VIMOVO modified-release tablets Indication

VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

 

VIMOVO modified-release tablets Generic Name

Naproxen / Esomeprazole

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - VIMOVO 500 mg/20 mg modified-release tablets (external site)

Related Learning Zones

Obesity CME series

Obesity CME series

This European Obesity Initiative CME series contains three online modules, which are ideal for healthcare professionals looking to widen their understanding of obesity as a serious medical illness. Each module is EACCME-accredited and free to complete. Successful completion of the series will earn participants a combined total of 5 European CME credits (ECMECs).

Prostate Cancer Learning Hub

Prostate Cancer Learning Hub

The Prostate Cancer Learning Hub has been designed with the busy healthcare professional in mind. The resource conveniently organises a range of up-to-date education content, reference materials and decision support tools, all focussing on prostate cancer. The disease awareness section provides you with access to a Prostate Cancer Knowledge Centre, which has been developed to provide you with easy to digest best practice guidance for the treatment and management of patients with prostate cancer.

VIMOVO modified-release Marketing Information

VIMOVO modified-release Generic Name
Naproxen / Esomeprazole
Marketing Company
AstraZeneca UK Ltd
Drug Type
POM
Date of Issue, Marketing Authority 05/11/2010

Related Drugs - Rheumatology

Back to top